GlaxoSmithKline (GSK) has announced d that it will not pursue a divestment of certain brands in its Established Products portfolio. The company announced in July 2014 that it had started a process to consider the divestment of certain North American and European brands, accounting for approximately £1 billion ($1.6 billion) in annual sales, in its Established Products portfolio.

In a statement, the company said it “has evaluated all bids received and has concluded, consistent with its key criteria of maximizng shareholder value, not to pursue divestment of these products.”

Source: GlaxoSmithKline